Do you think privatisation has negatively impact our research capabilities - especially looking at AMR and antibiotic development for long-term maintenance (not just short-term)

The Privatization Shift in Antibiotic Discovery

I examine how privatization has reshaped antibiotic development and our ability to tackle antimicrobial resistance (AMR). Over the past 30 years, major pharmaceutical companies have largely exited early-stage antibiotic R&D. In the 1980s, 18 firms actively pursued new classes; today, only a handful remain. This retreat stems from poor return on investment—new antibiotics often generate under $50 million annually once generics appear, compared to $1 billion+ for chronic-disease drugs.

Public-sector and small biotech efforts now shoulder 70% of early discovery according to WHO reports. Yet these groups lack the capital for large Phase 3 trials costing $100–$300 million. The result is a dried pipeline: only 12 new antibiotics approved between 2017–2022, most modifications of existing classes rather than novel mechanisms needed for long-term AMR control.

Long-Term Maintenance vs. Short-Term Profits

Privatization favors short-term blockbuster drugs over stewardship models that emphasize appropriate use and rotation to preserve efficacy. Long-term maintenance strategies—such as narrow-spectrum agents, microbiome-sparing compounds, and combination therapies—receive minimal venture funding. This directly affects patients like those in our CFP Weight Loss community managing diabetes and hypertension. Uncontrolled AMR raises infection risks during routine procedures, complicating metabolic recovery.

In my book, I outline how chronic low-grade inflammation from recurrent infections accelerates insulin resistance. When standard antibiotics lose potency, recovery timelines stretch, joint pain worsens, and weight-loss plateaus become harder to break. Middle-income Americans already facing insurance gaps for wellness programs cannot afford prolonged hospital stays from resistant infections.

Practical Steps for Individuals Facing AMR Risks

While systemic change lags, you can protect metabolic progress. First, prioritize prevention: maintain stable blood glucose (target HbA1c under 7% for most) because hyperglycemia fuels bacterial growth. My CFP Weight Loss method uses time-restricted eating windows of 10–12 hours to improve glycemic control without complex meal plans.

Second, adopt joint-friendly movement. Swimming or chair-based resistance circuits reduce infection risk by supporting lymphatic drainage without stressing painful knees. Aim for 150 minutes weekly—broken into 10-minute segments that fit busy schedules. Third, support immune resilience through targeted nutrition: 25–30 grams fiber daily from affordable sources like oats, beans, and frozen berries to nurture a healthy microbiome that naturally competes with pathogens.

Advocacy matters. Push for policy incentives like the PASTEUR Act that reward long-term antibiotic stewardship. Until privatization incentives realign, informed self-care remains our strongest defense against AMR while pursuing sustainable weight loss.

Building Sustainable Health Despite Research Gaps

The CFP Weight Loss framework bridges the gap privatization created by focusing on root metabolic drivers rather than symptom chasing. By lowering systemic inflammation through gradual, evidence-based habit shifts, you reduce reliance on antibiotics altogether. Start with one change this week—perhaps swapping one sugary drink for infused water—and track how energy and joint comfort improve within 14 days. Consistent small actions compound into resilience that no resistant bug can easily undermine.